Zeaxanthin
CAS 144-68-3
Zeaxanthin (CAS 144-68-3) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 185 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 23397.825 nM | 4 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| zeaxanthin | 39918 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Zeaxanthin used for in pharmaceutical contexts?
Zeaxanthin (CAS 144-68-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Zeaxanthin?
Zeaxanthin has 185 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal pain, Abdominal tenderness, Allergic sinusitis, Alopecia, Anaemia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Zeaxanthin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Zeaxanthin with EU status "permitted".
What clinical phase is Zeaxanthin in?
Zeaxanthin is rendered with ChEMBL max phase 3.